医药稳健科研股策略:年化收益率（26.7%）
本策略精选医药生物行业中研发投入高、净利润快速增长、估值合理的优质股票。通过量化财务指标，筛选出具备持续成长潜力的标的，并定期轮动调仓，力求在医药行业中获取稳健收益。
概要
核心指标
- 累计收益率: 78.85%
- 年化收益率: 26.7%
- 基准收益率: 19.17%
- 阿尔法: 0.21
- 夏普比率: 0.93
- 最大回撤: 22.09%
源码
查看AI策略代码
绩效
持仓详情
|
当日收盘价 | 当日市值 | 浮动收益/浮动收益率
|
|||||
|---|---|---|---|---|---|---|---|
| 2026-04-02 | 力生制药(002393.SZ) | 21.657896794798 | 24937 | 103 | 24.16 | 602477.92 | 62394.95/11.553% |
| 2026-04-02 | 通化东宝(600867.SH) | 9.0265914817798 | 62800 | 103 | 9.75 | 612300 | 45430.05/8.014% |
| 2026-04-02 | 浙江医药(600216.SH) | 13.994283947457 | 35490 | 253 | 15.94 | 565710.6 | 69053.46/13.904% |
| 2026-04-01 | 力生制药(002393.SZ) | 21.657896794798 | 24937 | 102 | 24.25 | 604722.25 | 64639.28/11.968% |
| 2026-04-01 | 通化东宝(600867.SH) | 9.0265914817798 | 62800 | 102 | 9.59 | 602252 | 35382.05/6.242% |
| 2026-04-01 | 浙江医药(600216.SH) | 13.994283947457 | 35490 | 252 | 16.23 | 576002.7 | 79345.56/15.976% |
| 2026-03-31 | 力生制药(002393.SZ) | 21.657896794798 | 24937 | 101 | 23.66 | 590009.42 | 49926.45/9.244% |
| 2026-03-31 | 通化东宝(600867.SH) | 9.0265914817798 | 62800 | 101 | 9.49 | 595972 | 29102.05/5.134% |
| 2026-03-31 | 浙江医药(600216.SH) | 13.994283947457 | 35490 | 251 | 16.07 | 570324.3 | 73667.16/14.833% |
| 2026-03-30 | 力生制药(002393.SZ) | 21.657896794798 | 25237 | 100 | 24.02 | 606192.74 | 59612.4/10.906% |
交易详情
| 2026-03-31 | 通化东宝(600867.SH) | 卖 | -900 | 9.5 | -8550 | ¥13.55 | 426.07 |
| 2026-03-31 | 浙江医药(600216.SH) | 买 | 500 | 16.58 | 8290 | ¥5 | 0 |
| 2026-03-31 | 力生制药(002393.SZ) | 卖 | -300 | 23.81 | -7143 | ¥12.14 | 645.63 |
| 2026-03-24 | 力生制药(002393.SZ) | 卖 | -700 | 20.92 | -14644 | ¥19.64 | -516.53 |
| 2026-03-24 | 浙江医药(600216.SH) | 买 | 1200 | 14.98 | 17976 | ¥5.39 | 0 |
| 2026-03-17 | 通化东宝(600867.SH) | 卖 | -1000 | 9.12 | -9120 | ¥14.12 | 93.41 |
| 2026-03-17 | 力生制药(002393.SZ) | 买 | 100 | 22.26 | 2226 | ¥5 | 0 |
| 2026-03-17 | 浙江医药(600216.SH) | 买 | 1000 | 16.5 | 16500 | ¥5 | 0 |
| 2026-03-10 | 通化东宝(600867.SH) | 卖 | -100 | 8.96 | -896 | ¥5.9 | -6.66 |
| 2026-03-10 | 力生制药(002393.SZ) | 买 | 800 | 22.11 | 17688 | ¥5.31 | 0 |
